ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer
-
Published:2024-04-10
Issue:9
Volume:26
Page:2351-2359
-
ISSN:1699-3055
-
Container-title:Clinical and Translational Oncology
-
language:en
-
Short-container-title:Clin Transl Oncol
Author:
Juan-Ribelles Antonio, Bautista Francisco, Cañete Adela, Rubio-San-Simón Alba, Alonso-Saladrigues Anna, Hladun Raquel, Rives Susana, Dapena Jose Luís, Fernández Jose María, Lassaletta Álvaro, Cruz Ofelia, Ramírez-Villar Gemma, Fuster Jose Luís, de Heredia Cristina Diaz, García-Ariza Miguel, Quiroga Eduardo, del Mar Andrés María, Verdú-Amorós Jaime, Molinés Antonio, Herrero Blanca, López Mónica, Márquez Catalina, Toboso María, Lendínez Frencisco, Sirvent Jose Gómez, Tallón María, Rodríguez Guiomar, Acha Tomás, Moreno LucasORCID, Fernández-Teijeiro Ana,
Abstract
Abstract
Introduction
ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation.
Methods
The platform’s database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up/conduct metrics since its creation until November 2023 were extracted.
Results
ECLIM-SEHOP has supported 47 studies: 29 clinical trials and 18 observational studies/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies: 16 trials recruiting 584 patients and nine observational studies/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months.
Discussion
ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.
Funder
Fundación Científica Asociación Española Contra el Cáncer
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Gatta G, Van der Zwan JM, Casali PG, Siesling S, Deitos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47:2493–511. https://doi.org/10.1016/j.ejca.2011.08.008. 2. Cañete Nieto A, Pardo Romaguera E, Muñoz López A, Valero Poveda S, Porta Cebolla S, Barreda Reines MS, et al. Cáncer infantil en España. Estadísticas 1980–2021. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València; 2022. 3. Peris-Bonet R. Incidencia y supervivencia del cáncer infantil. In: Madero L, Lassaleta A, Sevilla J, editors. Hematol y Oncol Pediátricas. 3rd ed. Madrid: Ergon; 2015. p. 263–70. 4. Cañete Nieto A, Pardo Romaguera E, Alfonso Comos P, Valero Poveda S, Fernández Férriz A, Porta Cebolla S, et al. Cáncer infantil en España. Estadísticas 1980–2022. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València (Edición preliminar); 2023. 5. Botta L, Gatta G, Capocaccia R, Stiller C, Cañete A, Dal Maso L, et al. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study. Lancet Oncol. 2022;23(12):1525–36. https://doi.org/10.1016/S1470-2045(22)00637-4.
|
|